Dr. Scorei has dedicated much of his research to the study of Calcium Fructoborate. To date, his investigations have resulted in nearly a dozen published studies on Calcium Fructoborate's unique chemical and biological properties and on new potential health benefits, including, most recently, the material's ability to modulate inflammatory and lipid blood markers in individuals exhibiting symptoms of primary osteoarthritis.
The BioBoron Research Institute, established in 2009 on a grant from the European Commission's Sectoral Operational Program for Increasing Economic Competitiveness, is equipped with state-of-the-art GMP laboratories for physico-chemical and biochemical research including spectroscopy, chromatography, molecular biology and cellular culture analyses.
The new collaboration between FutureCeuticals and the BioBoron Research Institute creates a potent discovery engine for the proprietary FruiteX-B® product. As part of the cooperative research, Dr. Scorei and his team will contribute to the chemical and biological differentiation of Calcium Fructoborate from other boron-based compounds and borate complexes.
John M. Hunter, General Manager at FutureCeuticals, advises that his company has seen a sharp spike in interest in and sales of FruiteX-B® over the last several years. "The alliance with the BioBoron Research Institute, and Dr. Scorei in particular, illustrates FutureCeuticals' ongoing commitment to enriching our scientific dossier on Calcium Fructoborate, and of providing increased value to our FruiteX-B® partners. Dr. Scorei's expertise, and his body of impressive existing and ongoing research into Calcium Fructoborate will greatly support current business initiatives as well as our planned aggressive push into Europe and other foreign markets", he added. The organization is wrapping up its own pilot clinical study on the effect of FruiteX-B® on participant-reported joint discomfort and diminished flexibility and inflammatory blood markers associated with osteoarthritis.
